Observations From the Rx & Illicit Drug Summit
It is interesting the faculty is starting to address the opioid crisis from the vantage point of chronic pain and ...
GLP-1 Drugs Can Do No Harm
The media hoopla around GLP-1 drugs create the impression that these medications are modern cure-alls. The truth is more nuanced.
Medical Populism and Vaccinations
Diseases once thought to be eliminated are now reappearing. Many blame the lack of vaccinations. The trend, however, is more ...
What’s Up Doc?
There I was, six years old, walking next to mom down 3rd Avenue, crossing 125th street. We were headed to ...
Bedside Manner: What It Means and Why It’s Important
What does it mean for a doctor, nurse, or other professional to have good bedside manners? We explain what bedside ...
Track Opioid Settlement Payouts
BrownGreer tracks much of this data but kept it private until KFF Health News negotiated to obtain it last year.
Federal Interference in the Practice of Medicine
Please understand that while I have continued my scientific studies, I would be much happier designing and building biomedical devices.
The First FBI Agent I Met
They are nothing like the men and women I served with in the Corps or my brothers and sisters in ...
7 Shocking Reasons Why You’re Your Best Advocate
Advocating for oneself is a fundamental aspect of navigating the complex world of healthcare. It is a mantra often repeated.
Details on the State AG’s Nationwide Opioid Settlement
In this writing we wish to share with you just some of the “evidence” we have gathered on the nationwide ...
The Surgeon’s Guide to Managing Acute Hand Pain
As a surgeon, you depend on your hands, making the common issue of hand pain a pressing one. Learn how ...
SEO for Modern Medicine
We detail unique SEO strategies being piloted at Daily Remedy that can help educate patients and combat misinformation.
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more